Abstract Details

Title Anti-beta 2 Glycoprotein I (Anti-?2 GPI) Antibodies in Neurology: A Clinical, Radiological and Therapeutic Analysis of 28 Patients

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 245

Objective

Background BACKGROUND: Anti-?2 GPI are part of the heterogeneous family of antiphospholipid (AP) antibodies and seem to be present in various neurological manifestations in addition to antiphospholipid syndrome (APS). Their associations with neurological inflammatory or vascular disease are not yet defined.

Design/Methods DESIGN/METHODS: AP antibodies, including anti-?2 GPI antibodies, are frequently tested in patients admitted to neurology with inflammatory or vascular manifestations. We systematically retrospectively reviewed the medical records of 28 consecutive patients hospitalized in the Neurology Department of Strasbourg University Hospital, France, in whom anti-?2 GPI antibodies (IgG and/or IgM) were positive and other antiphospholipid antibodies negative, from November 2005 to July 2011. Clinical, radiological, biological and therapeutic data and clinical course were studied.

Results RESULTS: Positive anti-?2 GPI antibodies were present in 28 patients (85.7% with IgM antibodies, 17.9% with IgG, 10.7% with both). Their mean age was 49.1 years. The final diagnosis was mainly inflammatory (25% with myelitis, 14.3% with optic neuritis) or vascular (14.3% with cerebral ischaemia, 7.1% with cerebral vasculitis). Brain MRI was performed in 89.3% of patients: we observed atypical lesions in 40.9%, and typical inflammatory and vascular lesions in 16% and 12%, respectively.

Conclusions CONCLUSIONS: The anti-?2 GPI seems to be involved in two types of neurological disease: vascular or inflammatory "multiple sclerosis-like" disease. These two types of patients frequently develop an autoimmune disease (multiple sclerosis [MS], systemic lupus erythematosus [SLE], APS). However, a large proportion of these patients had an undefined profile with aspecific cerebral lesions, and they require monitoring. This study confirms the interest of anti-?2 GPI in various neurological situations and raises questions about a separate entity at the border between APS and MS, which remains to be better defined in a larger cohort.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Jean Baptiste Chanson (Hopital Civil)	No disclosure on file
Nicolas Collongues, MD (Hopital Civil)	Nicolas Collongues, MD has nothing to disclose.
Tzu-Ching Wu, MD (UT Health McGovern Medical School)	Dr. Wu has nothing to disclose.
Frederic Blanc (Hopital Service de Neurologie)	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��